![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinical Trials
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
Regeneron Pharmaceuticals, Inc. announced detailed results from a Phase 2 proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma....
Articles
The Impact of COVID-19 on Rare Disease Clinical Trials
Barriers and triumphs of an underserved patient group.
It is undeniable that clinical trials for rare diseases are more challenging to design and execute. Unlike...
Clinical Trials
AiCure, OncoBay Clinical Partner to Improve Patient Care, Optimize Drug Development
AiCure and OncoBay Clinical announced a partnership to provide oncology sponsors with scalable, AI-powered insights to improve patient care and optimize drug development. A...
Clinical Trials
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in...
Clinical Trials
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
Sanofi and GSK announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate...
Clinical Trials
Parexel and NeoGenomics announce partnership to improve clinical trials
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, and...
Clinical Trials
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines administered by tablet, announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read